Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
ApexOnco Front Page
Recent articles
New data with pasritamig plus docetaxel support a recent pivotal start.
A deal with Jacobio is worth $100m up front.
Nenocorilant features among the latest industry projects newly into phase 1.
Two new PD-(L)1 x VEGF projects have entered the clinic.
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
The private ADC company is being wound down.
Ideate-Lung02 goes on global clinical hold.
